AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03804372
Drug: Tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
Trial: NCT04218357
Drug: Probenecid or placebo single administration
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: study drug administration with alcohol in the laboratory
Trial: NCT05349838
Drug: Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily oral tablet
Trial: NCT03289949
Drug: Psilocybine
RxNorm normalized name: Psilocybine
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of psilocybine.
Trial: NCT03289949
Drug: Ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of ketanserin.
Trial: NCT02473276
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: preservative free morphine given either via an epidural or intrathecal catheter
Trial: NCT02473276
Drug: Sterile normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile normal saline, given either via an epidural or intrathecal catheter
Trial: NCT00961792
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)
Trial: NCT03036462
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i.v. NaCl administration
Trial: NCT03504241
Drug: alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
Trial: NCT03504241
Drug: belatacept
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
Trial: NCT03504241
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
Trial: NCT03504241
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per protocol, and, only permitted in cases of sirolimus intolerance.
Trial: NCT03504241
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Per protocol, and, only permitted in cases of sirolimus intolerance.
Trial: NCT03662659
Drug: SOX
RxNorm normalized name: Vasoxyl
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaliplatin + tegafur/gimeracil/oteracil potassium
Trial: NCT03695952
Drug: Nivolumab or pembrolizumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
Trial: NCT01958021
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib (600 mg, in three 200 mg hard gelatin capsules or tablets) was administered orally once daily on Days 1-21 of each 28-day cycle.
Trial: NCT01958021
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
Trial: NCT00085982
Drug: Metreleptin
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation
Trial: NCT02806947
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus will be administered with a starting dose of 6 mg for patients older than 12 years, or 5 mg/m\^2 for patients ≤ 12 years. Trough levels will be routinely measured and sirolimus will be kept at maintenance dosing for target therapeutic levels for minimum duration through Day 56 post-randomization.
Trial: NCT02806947
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be administered at 2mg/kg/day x 3 days, and then tapered according to individual treating clinician judgment.
Trial: NCT02645851
Drug: fluid bolus
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to
Trial: NCT01804166
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.
Trial: NCT01804166
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
Trial: NCT02520921
Drug: Novel strategy Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin twice a day : enteric coated enteric coated aspirin given twice a day, 100 mg in the morning and 100 mg in the evening (i.e. 200mg/day)
Trial: NCT02520921
Drug: Conventional strategy Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin once day: enteric coated aspirin 100 mg in the morning (i.e. 100mg/day)
Trial: NCT02434328
Drug: Brolucizumab ophthalmic solution
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose
Trial: NCT02434328
Drug: Aflibercept ophthalmic solution
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose
Trial: NCT03496766
Drug: Tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipifarnib 600 mg will be administered until progression
Trial: NCT03243175
Drug: Apixaban 5 MG
RxNorm normalized name: apixaban 5 MG
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 5mg x 2 during 24 months
Trial: NCT05825885
Drug: E2
RxNorm normalized name: PE2
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: micronized E2 at a daily dose of 4-6mg,
Trial: NCT02798471
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 or 30 mg tablets for participants 12 years of age to \<18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
Trial: NCT02259855
Drug: Tipranavir
RxNorm normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02259855
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02259855
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02259855
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03899792
Drug: LOXO-292
RxNorm normalized name: Loxoprofene
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral LOXO-292
Trial: NCT02731612
Drug: lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atypical Antipsychotic
Trial: NCT00682318
Drug: Fish Oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;~Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;~Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days
Trial: NCT02359695
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
Trial: NCT03016091
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti PD-L1
Trial: NCT03715946
Drug: Nivolumab Injection
RxNorm normalized name: nivolumab Injection
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A fully human anti-programmed death 1 (PD-1) monoclonal antibody
Trial: NCT03083678
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.
Trial: NCT02421679
Drug: TNX-102 SL
RxNorm normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x 2.8mg TNX-102 SL Sublingual tablet
Trial: NCT00124735
Drug: Rocuronium bolus maintenance
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation
Trial: NCT00124735
Drug: rocuronium continuous infusion maintenance
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation
Trial: NCT00630487
Drug: Somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed doses for patients: MALE: \< 45y 0,4 mg, \> 45y 0,2mg FEMALE: \< 45y 0,5mg, \>45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
Trial: NCT00146172
Drug: neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HKI-272
Trial: NCT01086163
Drug: Omacor, omega-3 fatty acids in CAD patients
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omacor 1g versus 2g daily versus placebo
Trial: NCT02422615
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib capsules were administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle.
Trial: NCT02422615
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant was administered via intramuscular injections at a dose of 500mg every 28 days, starting on Day 1 of each cycle. In Cycle 1, an additional dose of Fulvestrant was given on Day 15.
Trial: NCT00990808
Drug: anacetrapib
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Intervention Name: MK0859\] MK0859 100 mg tablet once daily for 8 weeks.
Trial: NCT00990808
Drug: Comparator: atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
Trial: NCT00990808
Drug: Comparator: placebo to atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
Trial: NCT01184326
Drug: pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01184326
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02034292
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02034292
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02034292
Drug: APD791
RxNorm normalized name: APD791
DrugBank: APD791 (DB05227)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04029909
Drug: Gimatecan 0.6mg/m2/d
DrugBank: Gimatecan (DB06721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan
Trial: NCT04657172
Drug: Pilocarpine Ophthalmic
RxNorm normalized name: pilocarpine ophthalmic
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser
Trial: NCT01288443
Drug: Alirocumab
RxNorm normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two SC injections in the abdomen only.
Trial: NCT01288443
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
Trial: NCT00800579
Drug: GS-9411
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inhaled GS-9411 dissolved in sterile saline
Trial: NCT00220675
Drug: Erythropoietin infusion
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00739908
Drug: CX157 (TriRima)
RxNorm normalized name: CX157
DrugBank: CX157 (DB05205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six capsules administered three times a day for six weeks.
Trial: NCT01048476
Drug: Lutein and zeaxanthin
RxNorm normalized name: ICaps with Lutein and Zeaxanthin
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
Trial: NCT00003867
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01440933
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
Trial: NCT01646450
Drug: Icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib: 125mg, oral administration, three times per day.
Trial: NCT03002259
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone administered as a single IV injection after induction of anaesthesia, but before initiation of CPB. Prepare as a 20 mg/mL dexamethasone solution, made up with 0.9% saline to 10 ml.
Trial: NCT01461759
Drug: Doctaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles
Trial: NCT01461759
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles
Trial: NCT02203500
Drug: Lacidipine
RxNorm normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02203500
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04327843
Drug: Haloperidol Decanoate
RxNorm normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-acting injectable (LAI): Patients on oral haloperidol will be switched to haloperidol decanoate per manufacturer's package insert. Individuals not on antipsychotic medication at the time of screening assessment or who are on a different antipsychotic medication, will receive an oral tolerance test (OTT) consisting of up to 14 days of oral haloperidol 2-5 mg once or twice daily. If the OTT suggests good tolerability, the participant will then receive LAI (haloperidol decanoate) intramuscularly after completion of baseline assessments. Dosing of LAI will be as clinically indicated using conservative dosing to minimize drug-related adverse effects. In the CWRU studies, mean end-point dose of haloperidol decanoate was 68.0 mg, SD 21.1, Range 50-100 mg/monthly injection. It is anticipated that patients will continue on the same dose for 6 months, although dose changes will be permitted based upon clinical status. Each study participant will receive up to 8 injections during the study.
Trial: NCT01639131
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous gemcitabine 800mg/m2 on days 1 and 8
Trial: NCT01639131
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous docetaxel 70mg/m2 on day 8 of each 21 day cycle
Trial: NCT01639131
Drug: Filgrastim or Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: filgrastim (granulocyte colony-stimulating factor \[G-CSF\]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle
Trial: NCT01969916
Drug: Regadenoson
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
Trial: NCT03778541
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75mg/m2/d concurrent with radiotherapy, taken for at least 20 days.
Trial: NCT00495677
Drug: PF-00232798
RxNorm normalized name: PF-00232798
DrugBank: PF-232798 (DB14813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, 20 mg. once daily, 10 days
Trial: NCT00495677
Drug: PF-00232798
RxNorm normalized name: PF-00232798
DrugBank: PF-232798 (DB14813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, 150 mg. once daily, 10 days
Trial: NCT00495677
Drug: PF-00232798
RxNorm normalized name: PF-00232798
DrugBank: PF-232798 (DB14813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, 5 mg. once daily, 10 days
Trial: NCT00495677
Drug: PF-00232798
RxNorm normalized name: PF-00232798
DrugBank: PF-232798 (DB14813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, 40 mg. once daily, 10 days
Trial: NCT00495677
Drug: PF-00232798
RxNorm normalized name: PF-00232798
DrugBank: PF-232798 (DB14813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, 300 mg. once daily, 10 days
Trial: NCT00495677
Drug: PF-00232798
RxNorm normalized name: PF-00232798
DrugBank: PF-232798 (DB14813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, 400 mg. once daily, 10 days
Trial: NCT00176800
Drug: Tetrathiomolybdate (TM)
RxNorm normalized name: ethinyl estradiol
DrugBank: Tetrathiomolybdate (DB05088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.